2011
Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution
Cooper DL, Pratt K, Baker J, Medoff E, Conkling-Walsh A, Foss F, Snyder E, Yen W, Seropian SE. Late Afternoon Dosing of Plerixafor for Stem Cell Mobilization: A Practical Solution. Clinical Lymphoma Myeloma & Leukemia 2011, 11: 267-272. PMID: 21658654, DOI: 10.1016/j.clml.2011.03.014.Peer-Reviewed Original ResearchConceptsStem cell mobilizationEnough stem cellsMultiple myelomaCell mobilizationG-CSFPrevious mobilizationGranulocyte colony-stimulating factorNon-Hodgkin lymphomaStem cellsG-CSF mobilizationColony-stimulating factorPrevious chemotherapyPrevious therapyMobilization failurePoor mobilizationEvening injectionsCD34 countHigh riskPatientsPlerixaforCell countCost-effective useMyelomaLenalidomideChemotherapy
2003
Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease
Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Transplantation And Cellular Therapy 2003, 9: 170-176. DOI: 10.1016/s1083-8791(03)70006-8.Peer-Reviewed Original ResearchConceptsReduced-intensity preparative regimenHost dendritic cellsReduced-intensity regimenPreparative regimenTotal body irradiationDendritic cellsAcute GVHDChronic GVHDDC chimerismConventional regimenBody irradiationAllogeneic bone marrow transplantationAllogeneic bone marrow transplantAllogeneic stem cell transplantationExtensive chronic GVHDDevelopment of GVHDStem cell transplantationBone marrow transplantationBone marrow transplantExtracorporeal photophoresisHost diseaseMarrow transplantationSignificant morbidityMarrow transplantCell transplantation